Article
Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer.
The pharmacogenomics journal - 1 Jun 2014
Yao S, Sucheston L E, Zhao H, Barlow W E, Zirpoli G, Liu S, Moore H C F, Thomas Budd G, Hershman D L, Davis W, Ciupak G L, Stewart J A, Isaacs C, Hobday T J, Salim M, Hortobagyi G N, Gralow J R, Livingston R B, Albain K S, Hayes D F, Ambrosone C B
Abstract excerpt
Hematological and gastrointestinal toxicities are common among patients treated with cyclophosphamide and doxorubicin for breast cancer. To examine whether single-nucleotide polymorphisms (SNPs) in key pharmacokinetic genes were associated with risk of hematological or gastrointestinal toxicity, we analyzed 78 SNPs in ABCB1, ABCC1 and ALDH1A1 in 882 breast cancer patients enrolled in the SWOG trial S0221 and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.